Deciphera Pharmaceuticals

Deciphera Pharmaceuticals Dividend

Delisted·Jun 10, 2024

Dividend of Deciphera Pharmaceuticals (DCPH) as of Oct 31, 2026.

Dividend

0.00USD

Last updated:

How much dividend does Deciphera Pharmaceuticals 2026 pay?

According to the latest status from October 2026, Deciphera Pharmaceuticals paid a total of 0.00 USD per share in dividends within the last 12 months. With the current Deciphera Pharmaceuticals price of 25.59 USD, this corresponds to a dividend yield of - %. A dividend is paid times per year.

Historical Deciphera Pharmaceuticals Dividends

Historical Deciphera Pharmaceuticals Dividends
PaydateDividend

The Deciphera Pharmaceuticals Dividend history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Date
Dividend
Jan 1, 2022
0.00 USD
Jan 1, 2023
0.00 USD
Jan 1, 2024 (e)
0.00 USD
Jan 1, 2025 (e)
0.00 USD
Jan 1, 2026 (e)
0.00 USD
Jan 1, 2027 (e)
0.00 USD
Jan 1, 2028 (e)
0.00 USD
Jan 1, 2029 (e)
0.00 USD
The Deciphera Pharmaceuticals Dividend history
YEARDividendYoY
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Is the Deciphera Pharmaceuticals Dividend Safe?

Deciphera Pharmaceuticals has been increasing the dividend for 0 years.

Analysts expect a Dividend Cut of -100.00% for the current fiscal year.

Dividend Details

Understanding Deciphera Pharmaceuticals's Dividend Distributions

Deciphera Pharmaceuticals’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Deciphera Pharmaceuticals's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Deciphera Pharmaceuticals's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Deciphera Pharmaceuticals’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Deciphera Pharmaceuticals Stock analysis

What does Deciphera Pharmaceuticals do? Deciphera Pharmaceuticals Inc is a US biopharmaceutical company specializing in the research, development, and marketing of innovative therapeutic solutions for cancer patients. The company was founded in 2003 and is headquartered in Waltham, Massachusetts. Deciphera follows a diversified business model based on multiple pillars. On one hand, the company conducts its own research and development activities to develop new therapy approaches for cancer patients. Deciphera focuses on the research of kinase inhibitors, which offer promising approaches in cancer therapy. On the other hand, the company pursues a licensing strategy by acquiring and further developing already developed active ingredients for cancer therapies in order to make them available to patients. For this purpose, the company collaborates with various partner companies and leading academics and experts in the field of cancer therapy. Deciphera is also engaged in international collaboration through partnerships with local partners in Asia for the research of new cancer therapy approaches. The company invests significant efforts in research and development to constantly adapt its products to the latest scientific advances. Deciphera aims to develop effective and safe therapies for cancer patients that improve their quality of life and increase their chances of survival. The company relies on the research of kinase inhibitors that specifically target certain signaling pathways in cancer cells and thereby inhibit the growth of tumor cells. The company already has a number of products in clinical trials and approval processes that show promising results and are expected to be on the market soon. One promising drug is Ripretinib, dedicated to the cancer type GIST. The goal is to offer a range of cancer medications that have significant treatment success and offer customers high chances of success. Overall, Deciphera Pharmaceuticals is a dynamic and research-oriented company that utilizes the most innovative technologies to give hope to cancer patients and improve the treatment of cancer diseases. With its broad portfolio of active ingredients and therapy approaches, its international presence, and its dedicated research and development, Deciphera Pharmaceuticals Inc. is at the forefront when it comes to innovative cancer treatment therapies. Deciphera Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Deciphera Pharmaceuticals stock

Deciphera Pharmaceuticals paid dividends every year for the past 0 years.

Deciphera Pharmaceuticals is assigned to the 'Health' sector.

The dividends of Deciphera Pharmaceuticals are distributed in USD.

Dividend calendar 2026

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

All Key Metrics — Deciphera Pharmaceuticals